Press Release Summary:
Requiring as little as 50 pg of input DNA, Imprint(TM) DNA Modification Kit completely converts unmethylated cytosine to uracil in under 2 hr. Solution is based on Bisulfite DNA Modification technology, which enables scientists to determine methylation patterns throughout genome. Once deamination of cytosine to uracil is complete, resultant DNA product is suitable for downstream applications such as qPCR and bisulfite sequencing.
Original Press Release:
Sigma-Aldrich Launches Superior DNA Bisulfite Modification Kit
Imprint(TM) Modification Kit offers researchers fast, sensitive and accurate results
ST. LOUIS, July 10 -- Sigma-Aldrich (NASDAQ:SIAL) is pleased to announce the launch of the Imprint(TM) DNA Modification kit. This kit is based on Bisulfite DNA Modification technology licensed from Epigentek Group, a Brooklyn, New York based biotechnology company. The Imprint DNA Modification kit completely converts unmethylated cytosine to uracil in less than two hours and requires as little as 50 pg of input DNA. Once the deamination of cytosine to uracil is complete the resultant DNA product is suitable for downstream applications, including qPCR and bisulfite sequencing.
Bisulfite DNA conversion is a well-established technique that enables scientists to determine methylation patterns throughout the genome. The Imprint DNA Modification Kit offers researchers fast, sensitive and accurate results, enabling further downstream analyses of DNA methylation patterns and their impact on human health and development.
"Sigma-Aldrich is pleased to offer the best-in-class speed and sensitivity of the Imprint DNA Modification Kit, which enables users to rapidly research DNA methylation in various scientific applications," said Keith Jolliff, Director of Genomics and Functional Genomics at Sigma-Aldrich. "This complements an already robust product line to support the Epigenetic workflow, including DNA purification, qPCR, sequencing and post-reaction clean-up."
Adam Li, the Chief Scientific Officer at Epigentek, said, "We are very pleased with Sigma-Aldrich's decision to partner with Epigentek in the epigenetic field. This arrangement underscores Epigentek's position in the epigenetic arena, strengthens its strategy and portfolio, and is expected to benefit both companies' programs in developing new epigenetics technologies and products."
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at sigma-aldrich.com.
About Epigentek Group Inc.: Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company has developed a comprehensive portfolio of more than 400 proprietary products that are used all around the world by esteemed academia, leading pharmaceuticals, and cutting edge biotechnology companies. These unique products are specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. The company, particularly emphasizing speed and effectiveness in its technologies, continues to focus on epigenetic innovation and to extensively develop and enhance its product portfolio.
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616, email@example.com